What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe

Authors

  • Oriol Solà-Morales Fundació HiTT, Barcelona - Spain and Department of Basic Sciences, Universitat Internacional de Catalunya, Barcelona - Spain
  • Iga Lipska Health Policy Institute, Warsaw - Poland https://orcid.org/0000-0001-9600-1419
  • Francois Meyer Independent Consultant, Paris - France https://orcid.org/0009-0004-4675-0066
  • Pier-Luigi Canonico Department of Pharmaceutical Sciences, Università Piemonte Orientale, Novara - Italy
  • Herbert Altmann Department of Market Access, Cencora, Munich - Germany https://orcid.org/0009-0000-9609-562X

DOI:

https://doi.org/10.33393/grhta.2025.3354

Keywords:

EU HTA Regulation, HTA, Implementation policy

Abstract

There has been a lot of discussion on the technical aspects of the soon to be implemented European Union’s Health Technology Assessment (EU HTA) regulation. However, there has been limited discussion on the implementation aspects and the potential limitations from a policy perspective. In May 2024, a group of HTA experts with previous policy responsibilities met in Rome to propose some policy aspects to be considered.

As a result of the discussion, several proposals were made. Building mutual trust, improving collaboration and engaging all relevant stakeholders seems a must. Equally important are the communication aspects, and ensuring equal commitment by all parties, allocating the appropriate incentives at all levels. Finally, it is noted that the EU HTA regulation has to be seen from the perspective of a wider policy change within the large EU legal framework.

Downloads

Download data is not yet available.

References

IQVIA. EFPIA Patient WAIT Indicator. 2024. Online: https://www.efpia.eu/media/vtapbere/efpia-patient-wait-indicator-2024.pdf (Accessed October 2024)

European Commission. Q&A: Adoption of Regulation on Health Technology Assessment. Online https://ec.europa.eu/commission/presscorner/detail/en/qanda_21_6773 (Accessed October 2024)

Schuster V. EU HTA Regulation and Joint Clinical Assessment—Threat or opportunity? J Mark Access Health Policy. 2024;12(2):100-104. https://doi.org/10.3390/jmahp12020008 PMID:38808311

Published

2025-01-16

How to Cite

Solà-Morales, O., Lipska, I., Meyer, F., Canonico, P.-L., & Altmann, H. (2025). What is needed to successfully implement the EU HTA Regulation enabling broad patient access in Europe. Global and Regional Health Technology Assessment, 12(1), 7–8. https://doi.org/10.33393/grhta.2025.3354
Received 2024-10-23
Accepted 2024-11-30
Published 2025-01-16

Metrics